Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD.
| Title: | Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD. |
|---|---|
| Authors: | Kostareva I; Research Institute of Pediatric Oncology and Hematology of Nikolay Nikolayevich Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, 23 Kashirskoe Shosse, 115478 Moscow, Russia.; Kirgizov K; Research Institute of Pediatric Oncology and Hematology of Nikolay Nikolayevich Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, 23 Kashirskoe Shosse, 115478 Moscow, Russia.; Machneva E; Russian Children's Clinical Hospital of the Nikolay Ivanovich Pirogov Russian National Research Medical University, Ministry of Health of Russia, Leninsky Prospect 117, 117997 Moscow, Russia.; Ustyuzhanina N; Laboratory of Glycoconjugate Chemistry, Nikolay Dmitriyevich Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, 119991 Moscow, Russia.; Nifantiev N; Laboratory of Glycoconjugate Chemistry, Nikolay Dmitriyevich Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, 119991 Moscow, Russia.; Skvortsova Y; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia, 1 Samory Mashela St., 117997 Moscow, Russia.; Shubina I; Research Institute of Experimental Diagnostics and Therapy of Tumors of N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, 23 Kashirskoe Shosse, 115478 Moscow, Russia.; Reshetnikova V; Research Institute of Experimental Diagnostics and Therapy of Tumors of N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, 23 Kashirskoe Shosse, 115478 Moscow, Russia.; Center for Biomedical Engineering, National University of Science and Technology MISIS, Leninsky Prospect 4, 119049 Moscow, Russia.; Valiev T; Research Institute of Pediatric Oncology and Hematology of Nikolay Nikolayevich Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, 23 Kashirskoe Shosse, 115478 Moscow, Russia.; Varfolomeeva S; Research Institute of Pediatric Oncology and Hematology of Nikolay Nikolayevich Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, 23 Kashirskoe Shosse, 115478 Moscow, Russia.; Kiselevskiy M; Research Institute of Experimental Diagnostics and Therapy of Tumors of N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia, 23 Kashirskoe Shosse, 115478 Moscow, Russia.; Center for Biomedical Engineering, National University of Science and Technology MISIS, Leninsky Prospect 4, 119049 Moscow, Russia. |
| Source: | Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2022 Sep 03; Vol. 15 (9). Date of Electronic Publication: 2022 Sep 03. |
| Publication Type: | Journal Article; Review |
| Language: | English |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: Basel, Switzerland : MDPI, c2004- |
| Abstract: | Despite the achievements that have increased viability after the transplantation of allogeneic hematopoietic stem cells (aHSCT), chronic graft-versus-host disease (cGVHD) remains the main cause of late complications and post-transplant deaths. At the moment, therapy alternatives demonstrate limited effectiveness in steroid-refractory illness; in addition, we have no reliable data on the mechanism of this condition. The lack of drugs of choice for the treatment of GVHD underscores the significance of the design of new therapies. Improved understanding of the mechanism of chronic GVHD has secured new therapy goals, and organized diagnostic recommendations and the development of medical tests have ensured a general language and routes for studies in this field. These factors, combined with the rapid development of pharmacology, have helped speed up the search of medicines and medical studies regarding chronic GVHD. At present, we can hope for success in curing this formidable complication. This review summarizes the latest clinical developments in new treatments for chronic GVHD. |
| References: | Glycobiology. 2007 May;17(5):541-52. (PMID: 17296677); Eur J Haematol. 2020 May;104(5):361-375. (PMID: 31908057); Leuk Lymphoma. 2015 Mar;56(3):671-5. (PMID: 24913503); Blood. 2011 Jan 20;117(3):1061-70. (PMID: 20952687); Blood Adv. 2022 Aug 9;6(15):4392-4402. (PMID: 35617682); J Clin Oncol. 2007 Sep 20;25(27):4255-61. (PMID: 17878478); Carbohydr Res. 2011 Apr 1;346(5):540-50. (PMID: 21315320); J Hematol Oncol. 2022 Mar 7;15(1):22. (PMID: 35255929); Blood Adv. 2019 Apr 9;3(7):984-994. (PMID: 30936059); Blood Adv. 2019 Jul 23;3(14):2218-2229. (PMID: 31332045); Blood. 2019 Mar 14;133(11):1191-1200. (PMID: 30674472); Int J Hematol. 2016 Feb;103(2):243-50. (PMID: 26608364); Transfus Med Hemother. 2020 Jun;47(3):214-225. (PMID: 32595426); Front Immunol. 2021 Jun 30;12:673636. (PMID: 34276662); Rinsho Ketsueki. 2021;62(8):1281-1287. (PMID: 34497217); Leuk Lymphoma. 2018 Feb;59(2):372-380. (PMID: 28587506); Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. (PMID: 25385601); Blood Adv. 2020 Aug 11;4(15):3789-3794. (PMID: 32780849); Blood Adv. 2021 Nov 9;5(21):4521-4534. (PMID: 34543382); Biol Blood Marrow Transplant. 2018 Sep;24(9):1920-1927. (PMID: 29550629); Expert Rev Hematol. 2011 Jun;4(3):329-42. (PMID: 21668397); Adv Chronic Kidney Dis. 2020 Jan;27(1):56-66. (PMID: 32147003); Biol Blood Marrow Transplant. 2005 Dec;11(12):945-56. (PMID: 16338616); Am J Reprod Immunol. 2010 Jun;63(6):445-59. (PMID: 20331584); Cytotherapy. 2022 Mar;24(3):311-319. (PMID: 34711501); Transplant Cell Ther. 2021 Jul;27(7):545-557. (PMID: 33839317); Front Immunol. 2020 Oct 09;11:578314. (PMID: 33162993); Pediatr Pulmonol. 2020 Mar;55(3):631-637. (PMID: 31951682); Int J Mol Sci. 2019 Nov 28;20(23):. (PMID: 31795299); Blood. 2017 Nov 23;130(21):2243-2250. (PMID: 28924018); N Engl J Med. 2015 Jul 16;373(3):252-61. (PMID: 26176382); Blood Adv. 2022 Apr 12;6(7):2309-2318. (PMID: 34920451); Haematologica. 2020 Apr;105(4):1138-1146. (PMID: 31413093); Front Immunol. 2021 Aug 30;12:713358. (PMID: 34526990); Transplantation. 2004 Jan 15;77(1 Suppl):S29-31. (PMID: 14726767); Bone Marrow Transplant. 2009 Oct;44(7):393-403. (PMID: 19684626); Cell Rep Med. 2022 May 17;3(5):100614. (PMID: 35551746); Biol Blood Marrow Transplant. 2018 Jun;24(6):1125-1134. (PMID: 29289756); Biol Blood Marrow Transplant. 2020 May;26(5):835-844. (PMID: 31505228); Org Biomol Chem. 2016 Jan 14;14(2):598-611. (PMID: 26536063); Leukemia. 2020 May;34(5):1229-1240. (PMID: 32242050); Cancer J. 2019 Nov/Dec;25(6):386-393. (PMID: 31764119); Blood. 2007 Jul 1;110(1):9-17. (PMID: 17327406); Bone Marrow Transplant. 2004 Apr;33(7):729-34. (PMID: 14755315); J Cardiothorac Vasc Anesth. 2022 Jul;36(7):1880-1882. (PMID: 35537974); Biochimie. 2012 Feb;94(2):558-65. (PMID: 21945810); Best Pract Res Clin Haematol. 2008 Jun;21(2):357-72. (PMID: 18503998); Bone Marrow Transplant. 2020 Jul;55(7):1379-1387. (PMID: 32071418); Carbohydr Polym. 2020 Apr 15;234:115895. (PMID: 32070515); Lancet. 2004 May 1;363(9419):1439-41. (PMID: 15121408); Mar Drugs. 2013 Jul 12;11(7):2444-58. (PMID: 23857111); Blood. 2004 Aug 15;104(4):993-1001. (PMID: 15100152); Drugs. 2006;66(8):1041-57. (PMID: 16789791); Cytotherapy. 2016 Dec;18(12):1560-1563. (PMID: 27742233); Int J Hematol. 2013 Aug;98(2):206-13. (PMID: 23860964); Blood. 2000 Oct 1;96(7):2460-8. (PMID: 11001898); Biol Blood Marrow Transplant. 2017 Feb;23(2):211-234. (PMID: 27713092); Bull Exp Biol Med. 2021 Dec;172(2):250-253. (PMID: 34855084); J Pediatr Hematol Oncol. 2021 Apr 1;43(3):90-94. (PMID: 33560076); Biol Blood Marrow Transplant. 2016 Oct;22(10):1781-1791. (PMID: 27343720); Carbohydr Polym. 2022 Apr 1;281:119072. (PMID: 35074127); Blood Adv. 2019 Apr 9;3(7):969-979. (PMID: 30936057); Molecules. 2021 Apr 29;26(9):. (PMID: 33947107); Haematologica. 2017 Jul;102(7):1185-1191. (PMID: 28341735); Clin Cancer Res. 2017 Mar 1;23(5):1149-1155. (PMID: 28073846); Leuk Lymphoma. 2015 Mar;56(3):663-70. (PMID: 24913499); Front Immunol. 2018 May 16;9:1087. (PMID: 29868032); Pharmaceuticals (Basel). 2021 Oct 24;14(11):. (PMID: 34832856); Bone Marrow Transplant. 2017 Jun;52(6):859-862. (PMID: 28287644); Nat Rev Gastroenterol Hepatol. 2017 Dec;14(12):711-726. (PMID: 28951581); J Immunol. 2008 Nov 1;181(9):5956-62. (PMID: 18941184); Blood. 2017 Jan 5;129(1):13-21. (PMID: 27821504); Biol Blood Marrow Transplant. 2008 Oct;14(10):1163-1171. (PMID: 18804047); Biol Blood Marrow Transplant. 2017 Dec;23(12):2192-2198. (PMID: 28864140); Leukemia. 2022 Jul;36(7):1907-1915. (PMID: 35513703); Biol Blood Marrow Transplant. 2015 Aug;21(8):1343-59. (PMID: 25985921); Oncologist. 2022 Aug 5;27(8):685-693. (PMID: 35443042); Carbohydr Polym. 2017 Jul 1;167:20-26. (PMID: 28433155); World J Transplant. 2016 Dec 24;6(4):608-619. (PMID: 28058210); Blood. 2015 Jan 22;125(4):606-15. (PMID: 25398933); Haematologica. 2013 Mar;98(3):437-43. (PMID: 22899581); Mar Drugs. 2015 Feb 02;13(2):770-87. (PMID: 25648510); Bone Marrow Transplant. 2021 Sep;56(9):2079-2087. (PMID: 34218265); Exp Hematol. 2008 Aug;36(8):988-96. (PMID: 18410989); Transplantation. 2007 Jul 15;84(1):31-9. (PMID: 17627234); Blood. 2016 Apr 28;127(17):2144-54. (PMID: 26983850); Mar Drugs. 2020 Oct 28;18(11):. (PMID: 33126758); Int J Hematol. 2022 Sep;116(3):401-410. (PMID: 35511399); Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. (PMID: 25529383); Curr Opin Hematol. 2014 Mar;21(2):141-7. (PMID: 24468835); Carbohydr Res. 2008 Oct 13;343(15):2605-12. (PMID: 18619579); Carbohydr Polym. 2017 Jun 1;165:7-12. (PMID: 28363577); Blood. 2008 Aug 1;112(3):504-10. (PMID: 18480425); Biol Blood Marrow Transplant. 2011 Dec;17(12):1775-82. (PMID: 21621629); Nat Immunol. 2016 Nov;17(11):1322-1333. (PMID: 27595233); Int J Hematol Oncol. 2015 Aug;4(3):113-126. (PMID: 27182433); Blood. 2008 Oct 1;112(7):2667-74. (PMID: 18621929); J Vasc Res. 2008;45(6):529-37. (PMID: 18463418); Cold Spring Harb Perspect Med. 2013 Sep 01;3(9):a015487. (PMID: 24003247); Biol Blood Marrow Transplant. 2013 Feb;19(2):305-13. (PMID: 23092812); Transplant Cell Ther. 2022 Jul;28(7):390.e1-390.e10. (PMID: 35460929); JCI Insight. 2019 Mar 21;4(6):. (PMID: 30753169); Blood. 2002 May 15;99(10):3493-9. (PMID: 11986199); Blood Adv. 2021 Oct 26;5(20):4102-4111. (PMID: 34461633); Blood Adv. 2022 Apr 27;:. (PMID: 35475885); Blood. 2021 Dec 2;138(22):2278-2289. (PMID: 34265047); Mol Ther. 2022 Jun 1;30(6):2298-2314. (PMID: 35240319); Nat Rev Immunol. 2012 May 11;12(6):443-58. (PMID: 22576252); Cells. 2021 Aug 10;10(8):. (PMID: 34440819); Mar Drugs. 2018 Sep 13;16(9):. (PMID: 30216993); Ann N Y Acad Sci. 2016 Apr;1370(1):109-18. (PMID: 27270495); Pediatr Transplant. 2004 Oct;8(5):437-44. (PMID: 15367278); Carbohydr Polym. 2016 Nov 20;153:399-405. (PMID: 27561511); Front Immunol. 2020 Dec 17;11:607030. (PMID: 33391276); Blood Adv. 2021 Mar 9;5(5):1352-1359. (PMID: 33656537) |
| Grant Information: | . 075-15-2020-777 Ministry of Science and Higher Education of the Russian Federation |
| Contributed Indexing: | Keywords: graft-versus-host disease; hematopoietic stem cell transplantation; novel agents; oligosaccharides |
| Entry Date(s): | Date Created: 20220923 Latest Revision: 20220928 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC9503665 |
| DOI: | 10.3390/ph15091100 |
| PMID: | 36145321 |
| Database: | MEDLINE |
Journal Article; Review